Latest Period
Q1 2026
Security Snapshot
Protagonist Therapeutics, Inc - COMMON STOCK (PTGX) Institutional Ownership
CUSIP: 74366E102
13F Institutional Holders and Ownership History from Q3 2016 to Q1 2026
Institutions Reporting
317
Shares (Excl. Options)
78,748,068
Price
$105.40
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- PTGX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 78,748,068
- Total 13F value
- $8,296,612,447
- Portfolio coverage rank
- 0.01%
- Share change
- +6,394,269
- Value change
- +$705,562,894
- Number of holders
- 317
- Shares outstanding
- 63,608,245
- SEC-reported price per share
- $100.41
- Insider filing price
- $100.41
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PTGX - Protagonist Therapeutics, Inc - COMMON STOCK is tracked under CUSIP 74366E102.
- 317 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 311 to 317 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $6,175,433,604 to $8,296,612,447.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 317 institutions filings for Q1 2026.
Security key
74366E102
Latest holder period
Q1 2026
13F holders
317
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
PTGX full holder history
Protagonist Therapeutics, Inc SEC filings
Protagonist Therapeutics, Inc company facts
Protagonist Therapeutics, Inc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74366E102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
PTGX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 14% | -6.7% | $569,681,692 | -$33,813,734 | 8,575,669 | -5.6% | BlackRock, Inc. | 30 Sep 2025 |
| Farallon Capital Partners, L.P. | 10% | 0% | $545,701,455 | +$25,461,794 | 6,248,013 | +4.9% | Dapice Joshua J. | 31 Dec 2025 |
| RTW INVESTMENTS, LP | 8.1% | $405,989,003 | 5,059,053 | RTW Investments, LP | 31 Dec 2025 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.5% | $372,379,781 | 3,533,015 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $342,550,316 | 3,250,003 | Vanguard Capital Management | 31 Mar 2026 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 5.1% | $254,506,696 | 3,171,423 | Wellington Management Group LLP | 31 Dec 2025 | |||
| STATE STREET CORP | 4.9% | -6% | $328,511,142 | -$9,588,238 | 3,116,804 | -2.8% | STATE STREET CORPORATION | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 4.1% | -22% | $170,121,650 | -$43,187,804 | 2,560,916 | -20% | BVF PARTNERS L P/IL | 30 Sep 2025 |
| Deep Track Capital, LP | 2.8% | -51% | $113,973,353 | -$101,924,147 | 1,715,691 | -47% | Deep Track Capital, LP | 30 Sep 2025 |
As of 31 Mar 2026, 317 institutional investors reported holding 78,748,068 shares of Protagonist Therapeutics, Inc - COMMON STOCK (PTGX). This represents 124% of the company’s total 63,608,245 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
98%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15% | 9,779,369 | +0.65% | 0.02% | $1,030,745,507 |
| FARALLON CAPITAL MANAGEMENT LLC | 10% | 6,348,906 | +3.3% | 4.4% | $669,174,692 |
| UBS Group AG | 8.1% | 5,177,796 | +87% | 0.1% | $545,739,698 |
| RTW INVESTMENTS, LP | 8% | 5,059,053 | 0% | 5.3% | $533,224,186 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.7% | 3,599,644 | +14% | 0.07% | $379,402,479 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.5% | 3,481,211 | 0% | 0.02% | $366,919,639 |
| STATE STREET CORP | 4.9% | 3,116,749 | -2.6% | 0.01% | $328,505,345 |
| JANUS HENDERSON GROUP PLC | 4.5% | 2,891,527 | +9.1% | 0.15% | $304,866,424 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 2,805,896 | 0% | 0.01% | $295,741,438 |
| JOHNSON & JOHNSON | 3.9% | 2,449,183 | 0% | 40% | $258,143,888 |
| Invesco Ltd. | 3.4% | 2,164,670 | +38% | 0.03% | $228,156,218 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 1,669,371 | +15% | 0.01% | $175,982,148 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.6% | 1,665,497 | +19% | 0.02% | $175,545,000 |
| CITADEL ADVISORS LLC | 2.4% | 1,551,900 | +38% | 0.12% | $163,570,260 |
| Woodline Partners LP | 2.2% | 1,414,173 | +0.38% | 0.56% | $149,053,834 |
| BANK OF AMERICA CORP /DE/ | 2% | 1,295,434 | +49% | 0.01% | $136,538,743 |
| PERCEPTIVE ADVISORS LLC | 1.9% | 1,230,879 | -8.9% | 2.6% | $129,734,647 |
| JENNISON ASSOCIATES LLC | 1.7% | 1,072,011 | +224% | 0.08% | $112,989,961 |
| MORGAN STANLEY | 1.6% | 1,018,222 | +16% | 0.01% | $107,320,718 |
| ADAR1 Capital Management, LLC | 1.6% | 994,119 | -5.2% | 6.4% | $104,780,143 |
| Hood River Capital Management LLC | 1.3% | 829,285 | 0.88% | $87,406,639 | |
| GOLDMAN SACHS GROUP INC | 1.2% | 778,945 | -19% | 0.01% | $82,100,804 |
| Driehaus Capital Management LLC | 1.1% | 720,928 | -34% | 0.56% | $75,985,811 |
| FMR LLC | 1% | 661,997 | +23% | 0% | $69,774,496 |
| MARSHALL WACE, LLP | 0.99% | 628,075 | -39% | 0.07% | $66,199,102 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
39
Latest
Q1 2026
Rows shown
1-25 of 39
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 78,748,068 | $8,296,612,447 | +$705,562,894 | $105.40 | 317 |
| 2025 Q4 | 70,709,835 | $6,175,433,604 | +$99,663,953 | $87.34 | 311 |
| 2025 Q3 | 70,684,460 | $4,695,410,423 | +$4,458,380 | $66.43 | 274 |
| 2025 Q2 | 70,977,321 | $3,923,985,934 | +$344,775,786 | $55.27 | 273 |
| 2025 Q1 | 64,994,031 | $3,143,069,159 | +$116,416,679 | $48.36 | 273 |
| 2024 Q4 | 63,271,382 | $2,442,272,169 | +$44,242,054 | $38.60 | 240 |
| 2024 Q3 | 61,602,509 | $2,772,507,649 | -$40,480,651 | $45.00 | 238 |
| 2024 Q2 | 59,068,539 | $2,046,920,014 | -$15,105,959 | $34.65 | 187 |
| 2024 Q1 | 59,715,204 | $1,727,559,912 | +$80,356,864 | $28.93 | 183 |
| 2023 Q4 | 57,464,862 | $1,317,641,644 | +$12,220,647 | $22.93 | 155 |
| 2023 Q3 | 56,712,373 | $945,896,121 | -$53,252,231 | $16.68 | 142 |
| 2023 Q2 | 56,731,936 | $1,566,841,397 | +$104,873,016 | $27.62 | 163 |
| 2023 Q1 | 53,194,090 | $1,222,410,149 | +$179,899,701 | $23.00 | 135 |
| 2022 Q4 | 49,023,797 | $534,831,663 | +$12,387,471 | $10.91 | 135 |
| 2022 Q3 | 47,348,207 | $399,128,639 | -$50,141,212 | $8.43 | 129 |
| 2022 Q2 | 53,360,764 | $422,090,018 | -$73,694,821 | $7.91 | 125 |
| 2022 Q1 | 50,329,296 | $1,191,811,689 | -$6,168,618 | $23.68 | 136 |
| 2021 Q4 | 49,204,800 | $1,682,561,970 | +$93,460,895 | $34.20 | 144 |
| 2021 Q3 | 46,239,107 | $819,492,437 | -$246,905,195 | $17.72 | 126 |
| 2021 Q2 | 47,991,061 | $2,154,082,054 | +$179,883,058 | $44.88 | 136 |
| 2021 Q1 | 44,189,630 | $1,144,564,352 | +$27,791,318 | $25.90 | 124 |
| 2020 Q4 | 43,016,906 | $867,295,836 | +$98,827,896 | $20.16 | 124 |
| 2020 Q3 | 37,171,432 | $727,253,818 | +$62,067,302 | $19.55 | 91 |
| 2020 Q2 | 34,047,384 | $601,265,429 | +$210,058,150 | $17.66 | 82 |
| 2020 Q1 | 23,373,035 | $165,030,731 | +$1,225,355 | $7.06 | 75 |